New York, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Heparin Industry" - https://www.reportlinker.com/p06041564/?utm_source=GNW
4% over the analysis period 2020-2027. Low Molecular Weight Heparin (LMWH), one of the segments analyzed in the report, is projected to record a 2.3% CAGR and reach US$5.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Ultra-Low Molecular Weight Heparin (ULMWH) segment is readjusted to a revised 2.8% CAGR for the next 7-year period.
The U.S. Market is Estimated at $1.9 Billion, While China is Forecast to Grow at 4% CAGR
The Heparin market in the U.S. is estimated at US$1.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2027 trailing a CAGR of 4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.4% and 2.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1 Billion by the year 2027.
Unfractionated Heparin (UFH) Segment to Record 1.9% CAGR
In the global Unfractionated Heparin (UFH) segment, USA, Canada, Japan, China and Europe will drive the 1.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$683.1 Million in the year 2020 will reach a projected size of US$777.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 2% CAGR through the analysis period.
Select Competitors (Total 21 Featured) -
ATTWILL Vascular Technologies
Bristol-Myers Squibb Company
Corline Biomedical
Cosmo Pharmaceuticals
ExThera Medical Corporation
Gland Pharma Ltd.
GlaxoSmithKline PLC
Hebei Changshan Biochemical Pharmaceutical
Hepoligo
IBEX Technologies, Inc.
Read the full report: https://www.reportlinker.com/p06041564/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Heparin - Global Key Competitors Percentage Market Share in
2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Subcutaneous by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for Subcutaneous by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 3: World 15-Year Perspective for Subcutaneous by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 4: World Recent Past, Current & Future Analysis for
Intravenous by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 5: World Historic Review for Intravenous by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 6: World 15-Year Perspective for Intravenous by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 7: World Heparin Market Analysis of Annual Sales in US$
Million for Years 2012 through 2027
Table 8: World Recent Past, Current & Future Analysis for
Heparin by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 9: World Historic Review for Heparin by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 10: World 15-Year Perspective for Heparin by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets for Years 2012, 2021 & 2027
Table 11: World Recent Past, Current & Future Analysis for Low
Molecular Weight Heparin (LMWH) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 12: World Historic Review for Low Molecular Weight
Heparin (LMWH) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 13: World 15-Year Perspective for Low Molecular Weight
Heparin (LMWH) by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2021 & 2027
Table 14: World Recent Past, Current & Future Analysis for
Ultra-Low Molecular Weight Heparin (ULMWH) by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 15: World Historic Review for Ultra-Low Molecular Weight
Heparin (ULMWH) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 16: World 15-Year Perspective for Ultra-Low Molecular
Weight Heparin (ULMWH) by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2021 & 2027
Table 17: World Recent Past, Current & Future Analysis for
Unfractionated Heparin (UFH) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 18: World Historic Review for Unfractionated Heparin
(UFH) by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 19: World 15-Year Perspective for Unfractionated Heparin
(UFH) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2021 &
2027
Table 20: World Recent Past, Current & Future Analysis for
Porcine by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 21: World Historic Review for Porcine by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 22: World 15-Year Perspective for Porcine by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027
Table 23: World Recent Past, Current & Future Analysis for
Bovine by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 24: World Historic Review for Bovine by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 25: World 15-Year Perspective for Bovine by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027
Table 26: World Recent Past, Current & Future Analysis for
Other Sources by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 27: World Historic Review for Other Sources by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 28: World 15-Year Perspective for Other Sources by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
Heparin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in the United States for 2022 (E)
Table 29: USA Recent Past, Current & Future Analysis for
Heparin by Route Of Administration - Subcutaneous and
Intravenous - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 30: USA Historic Review for Heparin by Route Of
Administration - Subcutaneous and Intravenous Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 31: USA 15-Year Perspective for Heparin by Route Of
Administration - Percentage Breakdown of Value Sales for
Subcutaneous and Intravenous for the Years 2012, 2021 & 2027
Table 32: USA Recent Past, Current & Future Analysis for
Heparin by Product Type - Low Molecular Weight Heparin (LMWH),
Ultra-Low Molecular Weight Heparin (ULMWH) and Unfractionated
Heparin (UFH) - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 33: USA Historic Review for Heparin by Product Type - Low
Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight
Heparin (ULMWH) and Unfractionated Heparin (UFH) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 34: USA 15-Year Perspective for Heparin by Product Type -
Percentage Breakdown of Value Sales for Low Molecular Weight
Heparin (LMWH), Ultra-Low Molecular Weight Heparin (ULMWH) and
Unfractionated Heparin (UFH) for the Years 2012, 2021 & 2027
Table 35: USA Recent Past, Current & Future Analysis for
Heparin by Source - Porcine, Bovine and Other Sources -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 36: USA Historic Review for Heparin by Source - Porcine,
Bovine and Other Sources Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 37: USA 15-Year Perspective for Heparin by Source -
Percentage Breakdown of Value Sales for Porcine, Bovine and
Other Sources for the Years 2012, 2021 & 2027
CANADA
Table 38: Canada Recent Past, Current & Future Analysis for
Heparin by Route Of Administration - Subcutaneous and
Intravenous - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 39: Canada Historic Review for Heparin by Route Of
Administration - Subcutaneous and Intravenous Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 40: Canada 15-Year Perspective for Heparin by Route Of
Administration - Percentage Breakdown of Value Sales for
Subcutaneous and Intravenous for the Years 2012, 2021 & 2027
Table 41: Canada Recent Past, Current & Future Analysis for
Heparin by Product Type - Low Molecular Weight Heparin (LMWH),
Ultra-Low Molecular Weight Heparin (ULMWH) and Unfractionated
Heparin (UFH) - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 42: Canada Historic Review for Heparin by Product Type -
Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight
Heparin (ULMWH) and Unfractionated Heparin (UFH) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 43: Canada 15-Year Perspective for Heparin by Product
Type - Percentage Breakdown of Value Sales for Low Molecular
Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin
(ULMWH) and Unfractionated Heparin (UFH) for the Years 2012,
2021 & 2027
Table 44: Canada Recent Past, Current & Future Analysis for
Heparin by Source - Porcine, Bovine and Other Sources -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 45: Canada Historic Review for Heparin by Source -
Porcine, Bovine and Other Sources Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 46: Canada 15-Year Perspective for Heparin by Source -
Percentage Breakdown of Value Sales for Porcine, Bovine and
Other Sources for the Years 2012, 2021 & 2027
JAPAN
Heparin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Japan for 2022 (E)
Table 47: Japan Recent Past, Current & Future Analysis for
Heparin by Route Of Administration - Subcutaneous and
Intravenous - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 48: Japan Historic Review for Heparin by Route Of
Administration - Subcutaneous and Intravenous Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 49: Japan 15-Year Perspective for Heparin by Route Of
Administration - Percentage Breakdown of Value Sales for
Subcutaneous and Intravenous for the Years 2012, 2021 & 2027
Table 50: Japan Recent Past, Current & Future Analysis for
Heparin by Product Type - Low Molecular Weight Heparin (LMWH),
Ultra-Low Molecular Weight Heparin (ULMWH) and Unfractionated
Heparin (UFH) - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 51: Japan Historic Review for Heparin by Product Type -
Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight
Heparin (ULMWH) and Unfractionated Heparin (UFH) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 52: Japan 15-Year Perspective for Heparin by Product Type -
Percentage Breakdown of Value Sales for Low Molecular Weight
Heparin (LMWH), Ultra-Low Molecular Weight Heparin (ULMWH) and
Unfractionated Heparin (UFH) for the Years 2012, 2021 & 2027
Table 53: Japan Recent Past, Current & Future Analysis for
Heparin by Source - Porcine, Bovine and Other Sources -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 54: Japan Historic Review for Heparin by Source -
Porcine, Bovine and Other Sources Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 55: Japan 15-Year Perspective for Heparin by Source -
Percentage Breakdown of Value Sales for Porcine, Bovine and
Other Sources for the Years 2012, 2021 & 2027
CHINA
Heparin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in China for 2022 (E)
Table 56: China Recent Past, Current & Future Analysis for
Heparin by Route Of Administration - Subcutaneous and
Intravenous - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 57: China Historic Review for Heparin by Route Of
Administration - Subcutaneous and Intravenous Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 58: China 15-Year Perspective for Heparin by Route Of
Administration - Percentage Breakdown of Value Sales for
Subcutaneous and Intravenous for the Years 2012, 2021 & 2027
Table 59: China Recent Past, Current & Future Analysis for
Heparin by Product Type - Low Molecular Weight Heparin (LMWH),
Ultra-Low Molecular Weight Heparin (ULMWH) and Unfractionated
Heparin (UFH) - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 60: China Historic Review for Heparin by Product Type -
Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight
Heparin (ULMWH) and Unfractionated Heparin (UFH) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 61: China 15-Year Perspective for Heparin by Product Type -
Percentage Breakdown of Value Sales for Low Molecular Weight
Heparin (LMWH), Ultra-Low Molecular Weight Heparin (ULMWH) and
Unfractionated Heparin (UFH) for the Years 2012, 2021 & 2027
Table 62: China Recent Past, Current & Future Analysis for
Heparin by Source - Porcine, Bovine and Other Sources -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 63: China Historic Review for Heparin by Source -
Porcine, Bovine and Other Sources Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 64: China 15-Year Perspective for Heparin by Source -
Percentage Breakdown of Value Sales for Porcine, Bovine and
Other Sources for the Years 2012, 2021 & 2027
EUROPE
Heparin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Europe for 2022 (E)
Table 65: Europe Recent Past, Current & Future Analysis for
Heparin by Route Of Administration - Subcutaneous and
Intravenous - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 66: Europe Historic Review for Heparin by Route Of
Administration - Subcutaneous and Intravenous Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 67: Europe 15-Year Perspective for Heparin by Route Of
Administration - Percentage Breakdown of Value Sales for
Subcutaneous and Intravenous for the Years 2012, 2021 & 2027
Table 68: Europe Recent Past, Current & Future Analysis for
Heparin by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 69: Europe Historic Review for Heparin by Geographic
Region - France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 70: Europe 15-Year Perspective for Heparin by Geographic
Region - Percentage Breakdown of Value Sales for France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets
for Years 2012, 2021 & 2027
Table 71: Europe Recent Past, Current & Future Analysis for
Heparin by Product Type - Low Molecular Weight Heparin (LMWH),
Ultra-Low Molecular Weight Heparin (ULMWH) and Unfractionated
Heparin (UFH) - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 72: Europe Historic Review for Heparin by Product Type -
Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight
Heparin (ULMWH) and Unfractionated Heparin (UFH) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 73: Europe 15-Year Perspective for Heparin by Product
Type - Percentage Breakdown of Value Sales for Low Molecular
Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin
(ULMWH) and Unfractionated Heparin (UFH) for the Years 2012,
2021 & 2027
Table 74: Europe Recent Past, Current & Future Analysis for
Heparin by Source - Porcine, Bovine and Other Sources -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 75: Europe Historic Review for Heparin by Source -
Porcine, Bovine and Other Sources Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 76: Europe 15-Year Perspective for Heparin by Source -
Percentage Breakdown of Value Sales for Porcine, Bovine and
Other Sources for the Years 2012, 2021 & 2027
FRANCE
Heparin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in France for 2022 (E)
Table 77: France Recent Past, Current & Future Analysis for
Heparin by Route Of Administration - Subcutaneous and
Intravenous - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 78: France Historic Review for Heparin by Route Of
Administration - Subcutaneous and Intravenous Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 79: France 15-Year Perspective for Heparin by Route Of
Administration - Percentage Breakdown of Value Sales for
Subcutaneous and Intravenous for the Years 2012, 2021 & 2027
Table 80: France Recent Past, Current & Future Analysis for
Heparin by Product Type - Low Molecular Weight Heparin (LMWH),
Ultra-Low Molecular Weight Heparin (ULMWH) and Unfractionated
Heparin (UFH) - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 81: France Historic Review for Heparin by Product Type -
Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight
Heparin (ULMWH) and Unfractionated Heparin (UFH) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 82: France 15-Year Perspective for Heparin by Product
Type - Percentage Breakdown of Value Sales for Low Molecular
Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin
(ULMWH) and Unfractionated Heparin (UFH) for the Years 2012,
2021 & 2027
Table 83: France Recent Past, Current & Future Analysis for
Heparin by Source - Porcine, Bovine and Other Sources -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 84: France Historic Review for Heparin by Source -
Porcine, Bovine and Other Sources Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 85: France 15-Year Perspective for Heparin by Source -
Percentage Breakdown of Value Sales for Porcine, Bovine and
Other Sources for the Years 2012, 2021 & 2027
GERMANY
Heparin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Germany for 2022 (E)
Table 86: Germany Recent Past, Current & Future Analysis for
Heparin by Route Of Administration - Subcutaneous and
Intravenous - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 87: Germany Historic Review for Heparin by Route Of
Administration - Subcutaneous and Intravenous Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 88: Germany 15-Year Perspective for Heparin by Route Of
Administration - Percentage Breakdown of Value Sales for
Subcutaneous and Intravenous for the Years 2012, 2021 & 2027
Table 89: Germany Recent Past, Current & Future Analysis for
Heparin by Product Type - Low Molecular Weight Heparin (LMWH),
Ultra-Low Molecular Weight Heparin (ULMWH) and Unfractionated
Heparin (UFH) - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 90: Germany Historic Review for Heparin by Product Type -
Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight
Heparin (ULMWH) and Unfractionated Heparin (UFH) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 91: Germany 15-Year Perspective for Heparin by Product
Type - Percentage Breakdown of Value Sales for Low Molecular
Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin
(ULMWH) and Unfractionated Heparin (UFH) for the Years 2012,
2021 & 2027
Table 92: Germany Recent Past, Current & Future Analysis for
Heparin by Source - Porcine, Bovine and Other Sources -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 93: Germany Historic Review for Heparin by Source -
Porcine, Bovine and Other Sources Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 94: Germany 15-Year Perspective for Heparin by Source -
Percentage Breakdown of Value Sales for Porcine, Bovine and
Other Sources for the Years 2012, 2021 & 2027
ITALY
Table 95: Italy Recent Past, Current & Future Analysis for
Heparin by Route Of Administration - Subcutaneous and
Intravenous - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 96: Italy Historic Review for Heparin by Route Of
Administration - Subcutaneous and Intravenous Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 97: Italy 15-Year Perspective for Heparin by Route Of
Administration - Percentage Breakdown of Value Sales for
Subcutaneous and Intravenous for the Years 2012, 2021 & 2027
Table 98: Italy Recent Past, Current & Future Analysis for
Heparin by Product Type - Low Molecular Weight Heparin (LMWH),
Ultra-Low Molecular Weight Heparin (ULMWH) and Unfractionated
Heparin (UFH) - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 99: Italy Historic Review for Heparin by Product Type -
Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight
Heparin (ULMWH) and Unfractionated Heparin (UFH) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 100: Italy 15-Year Perspective for Heparin by Product
Type - Percentage Breakdown of Value Sales for Low Molecular
Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin
(ULMWH) and Unfractionated Heparin (UFH) for the Years 2012,
2021 & 2027
Table 101: Italy Recent Past, Current & Future Analysis for
Heparin by Source - Porcine, Bovine and Other Sources -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 102: Italy Historic Review for Heparin by Source -
Porcine, Bovine and Other Sources Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 103: Italy 15-Year Perspective for Heparin by Source -
Percentage Breakdown of Value Sales for Porcine, Bovine and
Other Sources for the Years 2012, 2021 & 2027
UNITED KINGDOM
Heparin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in the United Kingdom for 2022 (E)
Table 104: UK Recent Past, Current & Future Analysis for
Heparin by Route Of Administration - Subcutaneous and
Intravenous - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 105: UK Historic Review for Heparin by Route Of
Administration - Subcutaneous and Intravenous Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 106: UK 15-Year Perspective for Heparin by Route Of
Administration - Percentage Breakdown of Value Sales for
Subcutaneous and Intravenous for the Years 2012, 2021 & 2027
Table 107: UK Recent Past, Current & Future Analysis for
Heparin by Product Type - Low Molecular Weight Heparin (LMWH),
Ultra-Low Molecular Weight Heparin (ULMWH) and Unfractionated
Heparin (UFH) - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 108: UK Historic Review for Heparin by Product Type - Low
Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight
Heparin (ULMWH) and Unfractionated Heparin (UFH) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 109: UK 15-Year Perspective for Heparin by Product Type -
Percentage Breakdown of Value Sales for Low Molecular Weight
Heparin (LMWH), Ultra-Low Molecular Weight Heparin (ULMWH) and
Unfractionated Heparin (UFH) for the Years 2012, 2021 & 2027
Table 110: UK Recent Past, Current & Future Analysis for
Heparin by Source - Porcine, Bovine and Other Sources -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 111: UK Historic Review for Heparin by Source - Porcine,
Bovine and Other Sources Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 112: UK 15-Year Perspective for Heparin by Source -
Percentage Breakdown of Value Sales for Porcine, Bovine and
Other Sources for the Years 2012, 2021 & 2027
SPAIN
Table 113: Spain Recent Past, Current & Future Analysis for
Heparin by Route Of Administration - Subcutaneous and
Intravenous - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 114: Spain Historic Review for Heparin by Route Of
Administration - Subcutaneous and Intravenous Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 115: Spain 15-Year Perspective for Heparin by Route Of
Administration - Percentage Breakdown of Value Sales for
Subcutaneous and Intravenous for the Years 2012, 2021 & 2027
Table 116: Spain Recent Past, Current & Future Analysis for
Heparin by Product Type - Low Molecular Weight Heparin (LMWH),
Ultra-Low Molecular Weight Heparin (ULMWH) and Unfractionated
Heparin (UFH) - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 117: Spain Historic Review for Heparin by Product Type -
Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight
Heparin (ULMWH) and Unfractionated Heparin (UFH) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 118: Spain 15-Year Perspective for Heparin by Product
Type - Percentage Breakdown of Value Sales for Low Molecular
Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin
(ULMWH) and Unfractionated Heparin (UFH) for the Years 2012,
2021 & 2027
Table 119: Spain Recent Past, Current & Future Analysis for
Heparin by Source - Porcine, Bovine and Other Sources -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 120: Spain Historic Review for Heparin by Source -
Porcine, Bovine and Other Sources Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 121: Spain 15-Year Perspective for Heparin by Source -
Percentage Breakdown of Value Sales for Porcine, Bovine and
Other Sources for the Years 2012, 2021 & 2027
RUSSIA
Table 122: Russia Recent Past, Current & Future Analysis for
Heparin by Route Of Administration - Subcutaneous and
Intravenous - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 123: Russia Historic Review for Heparin by Route Of
Administration - Subcutaneous and Intravenous Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 124: Russia 15-Year Perspective for Heparin by Route Of
Administration - Percentage Breakdown of Value Sales for
Subcutaneous and Intravenous for the Years 2012, 2021 & 2027
Table 125: Russia Recent Past, Current & Future Analysis for
Heparin by Product Type - Low Molecular Weight Heparin (LMWH),
Ultra-Low Molecular Weight Heparin (ULMWH) and Unfractionated
Heparin (UFH) - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 126: Russia Historic Review for Heparin by Product Type -
Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight
Heparin (ULMWH) and Unfractionated Heparin (UFH) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 127: Russia 15-Year Perspective for Heparin by Product
Type - Percentage Breakdown of Value Sales for Low Molecular
Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin
(ULMWH) and Unfractionated Heparin (UFH) for the Years 2012,
2021 & 2027
Table 128: Russia Recent Past, Current & Future Analysis for
Heparin by Source - Porcine, Bovine and Other Sources -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 129: Russia Historic Review for Heparin by Source -
Porcine, Bovine and Other Sources Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 130: Russia 15-Year Perspective for Heparin by Source -
Percentage Breakdown of Value Sales for Porcine, Bovine and
Other Sources for the Years 2012, 2021 & 2027
REST OF EUROPE
Table 131: Rest of Europe Recent Past, Current & Future
Analysis for Heparin by Route Of Administration - Subcutaneous
and Intravenous - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 132: Rest of Europe Historic Review for Heparin by Route
Of Administration - Subcutaneous and Intravenous Markets -
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06041564/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
